Investors may miss opportunities or face setbacks if there's no rational basis for the P/S ratio. The moderate P/S ratio suggests investors anticipate a slowdown in revenue. Many investors, less bearish than analysts, hold onto their stocks, risking future disappointment if P/S aligns with growth outlook.
Analysts are forecasting that Prothena will reach break-even point before it might exhaust its cash runway. Given its impressive revenue growth and reduction in cash burn, Prothena appears well positioned to fund further growth with minimal shareholder dilution or borrowing.
Despite recent declines, the company's strong growth signals a potential investment opportunity. Market response to its revenue growth indicates interest despite lack of profits.
Overvaluation risk looms for Prothena's shares with high P/S ratio amid poor revenue and weak growth forecast. Investors may face disappointment if the share price realigns with the firm's bleak future outlook.
プロセナに関するコメント
• $アグリー・リアルティ (ADC.US)$: BofA Securities Upgrades Agree Realty (ADC) to Buy
• $アメリコールド・リアルティ・トラスト (COLD.US)$: BofA Securities Upgrades to Neutral from Underperform - PT $30 (from $28)
• $エコラボ (ECL.US)$: UBS Upgrades to Buy from Neutral - PT $205 (from $186)
• $リインシュアランス・グループ・オブ・アメリカ (RGA.US)$: Credit Suisse Upgrades to Neutral from Underperform - PT $122 (from $80)
• $ソーラーエッジ・テクノロジーズ (SEDG.US)$: Oppenheimer Upgrades to Out...
まだコメントはありません